Abbott Laboratories (NYSE:ABT) Shares Purchased by LVW Advisors LLC

LVW Advisors LLC grew its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 45.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,440 shares of the healthcare product maker's stock after purchasing an additional 3,552 shares during the period. LVW Advisors LLC's holdings in Abbott Laboratories were worth $1,294,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of ABT. City Holding Co. raised its position in Abbott Laboratories by 0.6% during the 4th quarter. City Holding Co. now owns 41,958 shares of the healthcare product maker's stock worth $4,746,000 after buying an additional 266 shares during the last quarter. Annex Advisory Services LLC raised its holdings in Abbott Laboratories by 4.5% during the fourth quarter. Annex Advisory Services LLC now owns 73,028 shares of the healthcare product maker's stock worth $8,260,000 after purchasing an additional 3,177 shares in the last quarter. Hall Laurie J Trustee boosted its holdings in Abbott Laboratories by 1.7% in the 4th quarter. Hall Laurie J Trustee now owns 64,543 shares of the healthcare product maker's stock valued at $7,300,000 after purchasing an additional 1,081 shares in the last quarter. Cascade Investment Group Inc. increased its position in Abbott Laboratories by 31.5% during the 4th quarter. Cascade Investment Group Inc. now owns 3,345 shares of the healthcare product maker's stock worth $378,000 after purchasing an additional 802 shares during the period. Finally, Grove Bank & Trust raised its stake in shares of Abbott Laboratories by 2.0% during the 4th quarter. Grove Bank & Trust now owns 39,626 shares of the healthcare product maker's stock worth $4,482,000 after buying an additional 782 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Trading Down 0.4 %

Shares of ABT traded down $0.46 on Monday, hitting $113.45. 6,443,213 shares of the stock traded hands, compared to its average volume of 4,199,178. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $121.64. The stock's 50 day moving average is $114.93 and its two-hundred day moving average is $112.87. The firm has a market capitalization of $196.78 billion, a P/E ratio of 34.48, a P/E/G ratio of 2.40 and a beta of 0.73. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32.

Abbott Laboratories Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be issued a dividend of $0.59 per share. This is a boost from Abbott Laboratories's previous quarterly dividend of $0.55. The ex-dividend date is Wednesday, January 15th. This represents a $2.36 annualized dividend and a dividend yield of 2.08%. Abbott Laboratories's dividend payout ratio (DPR) is 66.87%.

Analyst Ratings Changes

ABT has been the subject of several research analyst reports. Piper Sandler increased their price objective on Abbott Laboratories from $131.00 to $133.00 and gave the stock an "overweight" rating in a research report on Thursday, October 17th. Barclays raised their price objective on shares of Abbott Laboratories from $143.00 to $149.00 and gave the company an "overweight" rating in a research note on Tuesday, November 5th. Evercore ISI upped their target price on shares of Abbott Laboratories to $136.00 and gave the stock a "buy" rating in a research report on Thursday, January 2nd. Jefferies Financial Group boosted their price target on Abbott Laboratories from $120.00 to $125.00 and gave the stock a "hold" rating in a research note on Thursday, October 17th. Finally, Morgan Stanley raised their price objective on Abbott Laboratories from $107.00 to $117.00 and gave the company an "equal weight" rating in a research note on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $131.57.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.